Regional Oncology Research Center (Social Determinants of Health Supplement)

区域肿瘤学研究中心（保健品的社会决定因素）

• 批准号: 10764021
• 负责人: WILLIAM George NELSON
• 金额: $ 24.98万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-05-07 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10764021
• 关键词: African American; Age; Aging; Bone Marrow Transplantation; Cancer Burden; Cancer Center Support Grant; Cancer Control; Cancer Patient; Catchment Area; Cause of Death; Chemicals; Clinical Research; Clinical Trials; Communities; Comprehensive Cancer Center; Dedications; Defect; Detection; Diagnosis; Enrollment; Epidemiology; Epigenetic Process; Equipment and supply inventories; Functional Imaging; Funding; Future; Genetic; Genome; Goals; Health Professional; Healthcare Systems; Heart Diseases; Hematologic Neoplasms; Human; Human Characteristics; Immunotherapy; Incidence; Intervention; Intervention Studies; Intervention Trial; Invaded; Knowledge; Life; Life Expectancy; Life Style; Malignant Neoplasms; Maryland; Medical; Minority; Minority Participation; Molecular; Molecular Genetics; NCI Center for Cancer Research; National Cancer Institute; Neoplasm Metastasis; Oncology; Outcome; Patient Care; Patients; Peer Review; Peer Review Grants; Population; Population Group; Prevention; Productivity; Publications; Research; Research Personnel; Research Training; Resource Sharing; Science; Scientist; Screening for cancer; Services; Specimen; Therapeutic Studies; Training and Education; Translating; United States; Universities; Work; anticancer research; biomedical scientist; cancer care; cancer cell; cancer genetics; cancer health disparity; cancer imaging; cancer immunotherapy; cancer prevention; cancer therapy; cancer type; career development; improved; innovation; insight; member; molecular imaging; mortality; multidisciplinary; new technology; outcome disparities; precision oncology; programs; public health relevance; screening; social health determinants; structural biology; tool; trend; tumor immunology; tumorigenesis

ABSTRACT The Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins is dedicated to cancer research, education and training, and patient care, with the overarching goal of creating and applying new knowledge to improve prevention, screening, detection, diagnosis and treatment of cancer in Maryland (the SKCCC catchment area) and throughout the nation and the world. This application seeks continued Cancer Center Support Grant (CCSG) funding for SKCCC Research Programs and Shared Resources (SRs). Since the previous CCSG renewal in 2016, the SKCCC has eliminated three Research Programs and created one new Program. Now, the 285 Members, from 34 academic departments throughout Johns Hopkins University, populate seven Research Programs: the new Cancer Invasion and Metastasis Program, and the established Programs in Cancer Genetics and Epigenetics, Cancer Immunology, Cancer Molecular and Functional Imaging, Cancer Chemical and Structural Biology, Hematologic Malignancies and Bone Marrow Transplantation, and Cancer Prevention and Control. Twelve SRs provide state-of-the-art-or-better support for SKCCC research and researchers. SKCCC science encompasses discovery research into the molecular genetics and epigenetics of human tumorigenesis, clinical trials of new immunotherapies and other cancer treatments, and epidemiologic analyses of lifestyle influences on cancer mortality. Over the past funding period, SKCCC Members were exceptionally productive, authoring 3,775 publications (23% Intra- Programmatic, 22% Inter-Programmatic and 66% featuring external collaborators). SKCCC researchers garnered $78.5 million in current peer-reviewed grant support, including $44.9 million from the National Cancer Institute. The SKCCC continued to deliver its science to the bedside. From an average 6,374 new cancer patients treated per year from 2016–2020, an average of 1,647 new subjects were enrolled annually to interventional studies (26% of newly registered cancer patients); therapeutic studies accrued some 17% of cancer patients. In addition, the SKCCC has worked successfully to promote inclusion of minority and underserved patients with cancer in clinical research, yielding a slight increase in minority participation in interventional trials (22.3% in 2015 to 25.4% in 2020), while African American accrual to interventional trials remained steady (15.0% in 2015 and 15.6% in 2020). Moving forward, the SKCCC plans: (1) to promote new breakthroughs in fundamental cancer research that create paradigm-shifting insights into the nature of human cancers, (2) to translate this pipeline of discovery into practice-changing advances, (3) to overcome barriers responsible for disparities in cancer outcomes by enhancing the delivery of innovative cancer services throughout the state of Maryland catchment area, and (4) to integrate research training and career development of biomedical scientists and health care professionals into all cancer research endeavors.

摘要 约翰霍普金斯的西德尼·金梅尔综合癌症中心（SKCCC）致力于癌症 研究，教育和培训，以及病人护理，其总体目标是创造和应用新的 改善马里兰州癌症预防、筛查、检测、诊断和治疗的知识（the SKCCC集水区），并在全国和世界各地。本申请寻求持续的癌症 中心支持补助金（CCSG）资助SKCCC研究计划和共享资源（SR）。以来 在2016年CCSG更新后，SKCCC取消了三个研究项目，并创建了一个 新方案。现在，来自约翰霍普金斯大学34个学术部门的285名成员， 填充七个研究计划：新的癌症侵袭和转移计划，以及建立 癌症遗传学和表观遗传学，癌症免疫学，癌症分子和功能 影像学、癌症化学和结构生物学、血液肿瘤和骨髓 移植和癌症预防与控制。12个工作人员代表提供最先进或更好的支持， SKCCC研究和研究人员。SKCCC科学包括分子发现研究 人类肿瘤发生的遗传学和表观遗传学，新免疫疗法和其他癌症的临床试验 治疗，以及生活方式对癌症死亡率影响的流行病学分析。在过去的融资 在此期间，SKCCC成员的生产力非常高，共出版了3，775份出版物（23%是内部出版物）。 方案，22%的方案间和66%的外部合作者）。SKCCC研究人员 获得了7850万美元的同行评审赠款支持，其中4490万美元来自国家癌症研究所。 院SKCCC继续将其科学带到床边。从平均6,374例新发癌症 从2016年至2020年，每年平均入组1，647例新受试者， 干预性研究（占新登记癌症患者的26%）;治疗性研究占新登记癌症患者的17%。 癌症患者。此外，SKCCC还成功地促进了少数民族的融入， 临床研究中服务不足的癌症患者，使少数人参与临床研究的人数略有增加。 干预性试验（2015年为22.3%，2020年为25.4%），而非洲裔美国人参与干预性试验 保持稳定（2015年为15.0%，2020年为15.6%）。展望未来，SKCCC计划：（1）促进新的 基础癌症研究的突破，创造了对人类本质的范式转变见解， 癌症，（2）将这一发现转化为改变实践的进展，（3）克服障碍 通过加强创新癌症服务的提供， 整个马里兰州集水区，以及（4）整合研究培训和职业生涯 发展生物医学科学家和卫生保健专业人员参与所有癌症研究工作。